
Professor Athimalaipet Ramanan
Expertise
Current positions
Honorary Professor
Bristol Medical School (THS)
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Research interests
My research in the area of paediatric rheumatology includes:
- Randomised controlled trials of novel biological drugs in children with JIA associated uveitis. I am the Co-Chief Investigator of Sycamore Trial (RCT of adalimumab in JIA associated uveitis) funded by HTA/ARUK. I am also the Co-Chief Investigator of a trial of Tocilizumab in anti TNF refractory JIA associated uveitis.
- Leading on new agents for management of refractory arthritis in collaboration with industry
- Design and conduct studies in rare disease using novel study designs (Bayesian and Simon design)
- Looking at diagnostic markers and new therapies for MAS or secondary HLH
- Collaboration with colleagues in India on secondary HLH in Dengue fever
- Basic science studies on understanding pathogenesis of lupus nephritis
- Biomarkers in JIA and JIA associated uveitis.
- Associate Editor – Archives of Diseases in Childhood
- Editorial Board – Rheumatology
- Scientific Member, ARUK/MCRN Paediatric Rheumatology Clinical Studies Group
- Associate Director of ARUK funded only Paediatric Experimental Arthritis Treatment Centre leading on JIA-Uveitis and Industry workstreams
- Medical Advisor for National Rheumatoid Arthritis Society (NRAS) and National Ankylosing Spondylitis Society (NASS)
- Research Advisor for RCPCH Paediatric Rheumatology CSAC.
Projects and supervisions
Thesis supervisions
Publications
Recent publications
28/03/2023Infantile Takayasu arteritis
Rheumatology
Examining Health Outcomes in Juvenile Idiopathic Arthritis
ACR Open Rheumatology
Hiding in plain sight
Archives of Disease in Childhood
Juvenile idiopathic arthritis polygenic risk scores are associated with cardiovascular phenotypes in early adulthood
Pediatric Rheumatology
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY)
Lancet